Smokers Have Worse Prostate Cancer Outcomes


Prostate cancer patients who smoke may be more susceptible to complications from treatment, and have increased risk of side effects and disease recurrence.

Prostate cancer patients who continue to smoke have worse outcomes

Prostate cancer patients who smoke may be more susceptible to complications from their treatment, and at increased risk of side effects and disease recurrence, according to a new study.

Patients who were current smokers had a 40% relative increase of cancer relapse and were twice as susceptible to disease spread and death due to prostate cancer compared with their non-smoking counterparts. The results are published in BJU International.

"Less optimal tumor control outcomes among smokers could possibly be explained by the influence of less oxygen concentration within the treated tumors among smokers, which is known to lead to less sensitivity of the cells being killed off by radiation treatments," said study author Michael Zelefsky, MD, of the Memorial Sloan Kettering Cancer Center, in a statement. "Our findings point to the importance of physicians counseling their patients regarding the potential harms of smoking interfering with the efficacy of therapies and for increased risks of side effects."

Prior studies have provided evidence of a link between smoking and both incidence of prostate cancer and death from prostate cancer. While the incidence studies range in outcomes, the link between smoking and an increased mortality are more consistent. The current study aimed to confirm this link and investigate whether smoking resulted in worse toxicity from external beam radiation therapy (EBRT) for these patients.

Zelefsky and colleagues analyzed retrospective data from 2,358 patients who were treated with EBRT between 1988 and 2005; 49% of these patients were former smokers, 7.6% were current smokers, and 41% were never-smokers.

After undergoing EBRT, patients who were current smokers had a higher chance of side effects such as ­ urinary retention, urinary incontinence, and bladder hemorrhage compared with those who had no history of smoking.

Current smokers had a 40% increased risk of prostate-specific antigen (PSA) relapse compared with non-smokers (P = .03), while former smokers had a similar risk of PSA relapse compared with never-smokers. The authors also found that current smokers had a higher risk of distant metastases after EBRT. The 10-year likelihood of distant metastases-free survival was 72.2% for current smokers, 85.8% for former smokers, and 87.3% for never-smokers (P < .001).

Both current and former smokers had a greater risk of grade 2 and higher late onset genitourinary adverse events. Ten-year likelihood of high grade genitourinary toxicities were 14.6% for current smokers, 12.8% for former smokers, and 8.7% for never-smokers (P = .016).

According to the study authors, this study is one of the first large cohort studies of patients treated with radiotherapy for prostate cancer to show that “smoking can adversely influence survival outcomes and increase the risk of treatment-related toxicity.”

While prospective studies are needed to confirm these findings, oncologists should, in the meantime, “encourage patients to participate in smoking-cessation programs before therapy to potentially lower their risk of relapsing disease and post-treatment toxicities,” conclude the authors.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content